×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PASG – passage bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PASG
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/29
09:06 am
pasg
Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Wedbush. They set an "outperform" rating and a $4.00 price target on the stock.
High
Report
Passage Bio, Inc. (NASDAQ: PASG) is now covered by analysts at Wedbush. They set an "outperform" rating and a $4.00 price target on the stock.
11/21
10:52 am
pasg
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
Low
Report
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development [Yahoo! Finance]
11/14
06:30 pm
pasg
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
High
Report
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
11/14
11:13 am
pasg
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
Low
Report
Passage Bio, Inc. (NASDAQ: PASG) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $13.00 price target on the stock.
11/14
07:39 am
pasg
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
Medium
Report
Passage Bio Achieves Milestones in Gene Therapy Trials [Yahoo! Finance]
11/13
07:00 am
pasg
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
High
Report
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
11/6
07:00 am
pasg
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Medium
Report
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
10/24
07:00 am
pasg
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Medium
Report
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/11
05:33 pm
pasg
Form 4 Passage BIO, Inc. For: Dec 09 Filed by: ORBIMED ADVISORS LLC
Low
Report
Form 4 Passage BIO, Inc. For: Dec 09 Filed by: ORBIMED ADVISORS LLC
12/6
07:08 pm
pasg
Form 4 Passage BIO, Inc. For: Dec 04 Filed by: ORBIMED ADVISORS LLC
Low
Report
Form 4 Passage BIO, Inc. For: Dec 04 Filed by: ORBIMED ADVISORS LLC
12/4
07:03 pm
pasg
Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
High
Report
Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
12/4
06:57 pm
pasg
Form 144 Passage BIO, Inc. Filed by: ORBIMED CAPITAL LLC
High
Report
Form 144 Passage BIO, Inc. Filed by: ORBIMED CAPITAL LLC
11/27
06:11 pm
pasg
Form 4 Passage BIO, Inc. For: Nov 25 Filed by: Nichols Weston
High
Report
Form 4 Passage BIO, Inc. For: Nov 25 Filed by: Nichols Weston
11/14
05:22 pm
pasg
Form SCHEDULE 13G/A Passage BIO, Inc. Filed by: Erste Asset Management GmbH
High
Report
Form SCHEDULE 13G/A Passage BIO, Inc. Filed by: Erste Asset Management GmbH
11/14
05:03 pm
pasg
Form SCHEDULE 13G Passage BIO, Inc. Filed by: Erste Asset Management GmbH
High
Report
Form SCHEDULE 13G Passage BIO, Inc. Filed by: Erste Asset Management GmbH
11/14
12:03 pm
pasg
Form SC 13G Passage BIO, Inc. Filed by: Vestal Point Capital, LP
Low
Report
Form SC 13G Passage BIO, Inc. Filed by: Vestal Point Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Form 8-K Passage BIO, Inc. For: Mar 26
25.5%
3/24 Passage Bio (NASDAQ: PASG) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 12.2%
4/10 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 10.1%
5/1 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. 8.1%
3/25 Passage Bio (NASDAQ: PASG) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 5.1%
3/9 Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares 4.6%
2/28 Passage Bio shares soar 19% in their trading debut despite massive market selloff [MarketWatch] 3.3%
3/3 Form 4 Passage BIO, Inc. For: Mar 03 Filed by: Cale Edgar B. 3.0%
3/5 Bankers try to keep IPO party going amid coronavirus market jitters [Reuters] 2.3%
4/14 Form 8-K Passage BIO, Inc. For: Apr 10 2.1%
3/24 Passage Bio (NASDAQ: PASG) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 12.2%
4/10 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 10.1%
5/1 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. 8.1%
3/25 Passage Bio (NASDAQ: PASG) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 5.1%
3/9 Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares 4.6%
2/28 Passage Bio shares soar 19% in their trading debut despite massive market selloff [MarketWatch] 3.3%
3/3 Form 4 Passage BIO, Inc. For: Mar 03 Filed by: Cale Edgar B. 3.0%
3/5 Bankers try to keep IPO party going amid coronavirus market jitters [Reuters] 2.3%
4/14 Form 8-K Passage BIO, Inc. For: Apr 10 2.1%
TOP News Decliners
3/15
Coronavirus and market volatility shuts down the IPO market for potential listings like Airbnb [CNBC]
-33.8%
3/25 Form 4 Passage BIO, Inc. For: Mar 24 Filed by: Countouriotis Athena -19.8%
3/6 Form SC 13G Passage BIO, Inc. Filed by: Vivo Capital VIII, LLC -9.4%
3/26 Form SEC STAFF LETTER Passage BIO, Inc. -8.1%
4/21 FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis -7.4%
3/12 Form 3/A Passage BIO, Inc. For: Feb 27 Filed by: Ratcliffe Liam -7.1%
3/2 Form 4 Passage BIO, Inc. For: Feb 27 Filed by: SQUINTO STEPHEN P -7.0%
3/12 Form SC 13G Passage BIO, Inc. Filed by: Access Industries Holdings LLC -6.7%
4/23 Passage Bio (NASDAQ: PASG) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
4/3 Form 8-K Passage BIO, Inc. For: Apr 03 -3.9%
3/25 Form 4 Passage BIO, Inc. For: Mar 24 Filed by: Countouriotis Athena -19.8%
3/6 Form SC 13G Passage BIO, Inc. Filed by: Vivo Capital VIII, LLC -9.4%
3/26 Form SEC STAFF LETTER Passage BIO, Inc. -8.1%
4/21 FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis -7.4%
3/12 Form 3/A Passage BIO, Inc. For: Feb 27 Filed by: Ratcliffe Liam -7.1%
3/2 Form 4 Passage BIO, Inc. For: Feb 27 Filed by: SQUINTO STEPHEN P -7.0%
3/12 Form SC 13G Passage BIO, Inc. Filed by: Access Industries Holdings LLC -6.7%
4/23 Passage Bio (NASDAQ: PASG) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%
4/3 Form 8-K Passage BIO, Inc. For: Apr 03 -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: